<unk>  is believed to have some positive effects in the treatment of Ménière's disease and vertigo. There have been studies of the use of<unk>  which showed a reduction in symptoms of vertigo and to a lesser extent, tinnitus, in subjects, but conclusive evidence is lacking at present. Oral<unk>  has been approved for the treatment of Ménière’s disease and vestibular vertigo in more than 80 countries worldwide, and has been reportedly prescribed more than 130 million patients. However,<unk>  has not been approved for marketing in the United States for the past few decades, and there is disagreement about its efficacy. The Cochrane Library concluded in 2001 that “Most trials suggested a reduction of vertigo with<unk>  and some suggested a reduction in tinnitus but all these effects may have been caused by bias in the methods. One trial with good methods showed no effect of<unk>  on tinnitus compared with placebo in 35 patients. None of the trials showed any effect of<unk>  on hearing loss. No serious adverse effects were found with<unk> .”<unk>  is also undergoing clinical trials for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
Betahistine
Allergan
Methacholine
Caffeine
Dihydroergotamine
Theobromine
Histamine dihydrochloride
Antihistamine